Your browser doesn't support javascript.
loading
Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.
Ströjby, Salina; Eberstål, Sofia; Svensson, Andreas; Fritzell, Sara; Bexell, Daniel; Siesjö, Peter; Darabi, Anna; Bengzon, Johan.
Afiliación
  • Ströjby S; Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden.
  • Eberstål S; Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden. Electronic address: sofia.eberstal@med.lu.se.
  • Svensson A; Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden.
  • Fritzell S; Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.
  • Bexell D; Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden; Translational Cancer Research, Lund University, Medicon Village 404:C3, Scheelevägen 2, SE-223 81 Lund, Sweden.
  • Siesjö P; Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.
  • Darabi A; Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Barngatan 2B, SE-221 85 Lund, Sweden.
  • Bengzon J; Bengzon Group, Lund Stem Cell Center, Division of Neurosurgery, Department of Clinical Sciences, Lund University, BMC B10, SE-221 84 Lund, Sweden.
J Neuroimmunol ; 274(1-2): 240-3, 2014 Sep 15.
Article en En | MEDLINE | ID: mdl-25086876
Bone marrow-derived mesenchymal stromal cells (MSCs) target glioma extensions and micro-satellites efficiently when implanted intratumorally. Here, we report that intratumoral implantation of MSCs and peripheral immunotherapy with interferon-gamma (IFNγ) producing tumor cells improve the survival of glioma-bearing rats (54% cure rate) compared to MSC alone (0% cure rate) or immunotherapy alone (21% cure rate) by enforcing an intratumoral CD8(+) T cell response. Further analysis revealed that the MSCs up-regulate MHC classes I and II in response to IFNγ treatment in vitro and secrete low amounts of immunosuppressive molecules prostaglandin E2 and interleukin-10.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Glioma / Inmunoterapia Límite: Animals Idioma: En Revista: J Neuroimmunol Año: 2014 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Glioma / Inmunoterapia Límite: Animals Idioma: En Revista: J Neuroimmunol Año: 2014 Tipo del documento: Article País de afiliación: Suecia